BioNTech SE (BVMF:B1NT34)

Market Cap	112.37B -29.6%
Revenue (ttm)	18.56B +4.3%
Net Income	-7.35B
EPS	-30.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173
Average Volume	1,302
Open	28.92
Previous Close	29.67
Day's Range	28.71 - 28.92
52-Week Range	25.78 - 43.61
Beta	1.53
RSI	32.38
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 7,807
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1NT34

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.

Financial numbers in EUR